Norway· NO-ID_FE446313-5031-4B91-8827-908A03D03B0A
Imfinzi
A durvalumab product containing durvalumab, registered in Norway by AstraZeneca AB (2). The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Durvalumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF03 (durvalumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Durvalumab · ATC L01FF03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of durvalumab costs, country by country.
Normalised to the WHO defined daily dose (53.6 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Durvalumab · price per daily dose (53.6 mg)
USD · FX 28 Sept 2026
- CH Switzerland$274.31
The record
At a glance
FEST (Norway)- Active substance
- Durvalumab
- Manufacturer
- AstraZeneca AB (2)
- Country
- Norway (NO)
- ATC code
- L01FF03
- ATC class
- Durvalumab
- Defined daily dose
- 53.6 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 5
2 priced- no_merkevare_idID_FE446313-5031-4B91-8827-908A03D03B0A
- no_varenummer5021572.4NOK 8207.9
- no_varenummer05921110NOK 33743.3
- gtin5000456030601
- gtin5000456030588
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
82 interactions on record for durvalumab.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Durvalumab · interactions on record
82 records
- 30 severe
- 45 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Durvalumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandImfinzi2care4 ApS
- CzechiaIMFINZIAstraZeneca AB, Södertälje
- BelgiumImfinzi 50 mg/mlAstraZeneca
- SwedenImfinzi 50 mg/ml Koncentrat till infusionsvätska, lösningAstraZeneca AB
- IrelandIMFINZI 50 mg/ml concentrate for solution for infusion.AstraZeneca AB
- IcelandImfinziAstraZeneca AB
- PolandImfinziAstraZeneca AB
- United StatesIMFINZIAstraZeneca Pharmaceuticals LP
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Imfinzi
- Liechtenstein · Imfinzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b94544b0-4f90-4049-8edd-ce2f95ca0b99 GET /v1/drugs/b94544b0-4f90-4049-8edd-ce2f95ca0b99?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Durvalumab",
"merkevare_id": "ID_FE446313-5031-4B91-8827-908A03D03B0A",
"name_form_strength": "Imfinzi kons til inf oppl 50 mg/ml",
"prescription_group": "C"
}See everything about durvalumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.